Institut’ DERMed Chromabright Serum
Institut’ DERMed announced their new Chromabright Serum, a cutting edge new active for skin brightening, is now available for purchase.
This revolutionary hydroquinone-free serum formulated with Chromabright and Glycolic Acid fades dark brown discoloration and renews the skin’s surface for a radiant, luminous complexion.
Chromabright, a new patented active molecule for skin brightening, is proven to have higher melanogenesis inhibition than Arbutin, MAP and Kojic Acid, and the same depigmenting effect as hydroquinone. Chromabright will stimulate collagen production, protect against photo-aging, while preventing premature aging, hyperpigmentation and acne.
“With only three of four days of use you will notice lightening, brightening and greater clarity for all skin types and ethnicities. And unlike other agents Chromabright actually induces a significant lightening effect on the skin as well as protects the skin against photo-damage. It’s really exciting for me to be offering Chromabright as an true alternative to hydroquonione,” Founder of Institut’ DERMed Lyn Ross stated.
Chromabright Serum is available at the Institut’ DERMed Medical Spa located in Atlanta, or online.
About Institut’ DERMed
The Institut’ DERMed line of cosmeceutical skin care products (idermed.com / idermedstore.com) contain the highest concentration of active ingredients available without prescription. Years of research and study with chemists went into the creation of these natural quality formulations designed to treat age- related skin conditions.
Master Esthetician Lyn Ross founded Institut’ DERMed 27 years ago with the goal of empowering skin care specialists with knowledge and proven treatment systems for optimal success. The company, located in Atlanta, currently consists of a med-spa, a full line of cosmeceutical products distributed to spa’s nationally and internationally and the Institut’ DERMed College of Advanced Aesthetics.
See Also:
If you enjoyed this post, please consider leaving a comment, subscribe to the feed and get future articles delivered to your feed reader or follow us on Twitter.
Comments
No comments yet.
Leave a comment